Strategy

European biotech searches for growth capital

Read more

Case study - the merits of adaptive trial design

Read more

Seismic shift ahead for drug pricing

Read more

Drugs for orphan diseases are no longer rare

Read more

Versant Ventures eyes start-ups in Europe

Read more

JP Morgan forum ends on a positive note

Read more

Market Commentary: How risky are European biotechs?

Read more

Cheap capital gives rise to integrated pharma R&D

Read more

Commentary: Thought disruption in R&D discovery

Read more

Market Analysis: The outlook for European pharma

Read more